Keyphrases
Gastroesophageal Varices
100%
Carvedilol
100%
Cirrhosis
100%
Confidence Interval
66%
Risk Ratio
50%
Upper Gastrointestinal Bleeding
50%
Serious Adverse Events
41%
Secondary Prevention
33%
Primary Prevention
33%
Nadolol
16%
Cochrane
16%
Propranolol
16%
Hepatobiliary
16%
Beneficial Effects
16%
Randomized Clinical Trial
16%
Hepatic Venous Pressure Gradient
16%
Non-serious
16%
Clinical Outcomes
16%
Harmful Effects
16%
Embase
8%
Bleeding Risk
8%
Review Authors
8%
Hemodynamic Response
8%
Publication Status
8%
Primary Outcome Measure
8%
Double-blind Randomized Clinical Trial
8%
Portal Hypertension
8%
Extracted Data
8%
Risk Reduction
8%
Meta-analysis
8%
High Risk
8%
Lack of Information
8%
Esophageal Varices
8%
Event Risk
8%
Mortality Data
8%
MEDLINE
8%
Inclusion Criteria
8%
Risk Response
8%
Risk of Bias
8%
Cochrane Central Register of Controlled Trials
8%
Search Methods
8%
Portal Pressure
8%
Selection Criteria
8%
Bleeding
8%
Bias Control
8%
Science Citation Index
8%
Number of Participants
8%
Manual Search
8%
Blocking Effect
8%
Trial Duration
8%
Nursing and Health Professions
Liver Cirrhosis
100%
Beta Adrenergic Receptor Blocking Agent
100%
Carvedilol
100%
Varicosis
100%
Confidence Interval
66%
Upper Gastrointestinal Bleeding
50%
Adverse Event
41%
Secondary Prevention
33%
Primary Prevention
33%
Venous Pressure
16%
Pressure Gradient
16%
Propranolol
16%
Clinical Outcome
16%
Bleeding
8%
Portal Vein Blood Pressure
8%
Portal Hypertension
8%
Cochrane Library
8%
Embase
8%
Meta Analysis
8%
SciSearch
8%
Medicine and Dentistry
Beta Adrenergic Receptor Blocking Agent
100%
Varices
100%
Liver Cirrhosis
100%
Upper Gastrointestinal Bleeding
50%
Adverse Event
41%
Secondary Prevention
33%
Primary Prevention
33%
Randomized Clinical Trial
25%
Propranolol
16%
Venous Pressure
16%
Hemodynamic
16%
Nadolol
16%
Portal Venous Pressure
8%
Meta-Analysis
8%
Portal Hypertension
8%
Esophageal Varices
8%
Bleeding
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cirrhosis
100%
Carvedilol
100%
Varicosis
100%
Beta Adrenergic Receptor Blocking Agent
100%
Upper Gastrointestinal Bleeding
50%
Adverse Event
41%
Randomized Clinical Trial
25%
Propranolol
16%
Nadolol
16%
Portal Hypertension
8%
Esophagus Varices
8%
Bleeding
8%